Tissue Regenix Group Achieves First Pre-Tax Profit

Tissue Regenix (TRX) has announced its first-ever pre-tax profit for the first half of 2024, following seven consecutive periods of strong growth. The company, which specializes in the development and commercialization of proprietary processing technologies for soft tissue (dCELL®) and bone (BioRinse®) repair, has a wide range of products in biosurgery, orthopaedics, and dental markets.

Significant investments in tissue processing and manufacturing capacity, along with robust commercial partnerships and a focused “4S” strategy, have been key drivers of TRX's recent performance. The company is poised to invest in Phase 2 of its capacity expansion program, which could potentially boost group sales to $100 million.